Authors:
VJ Harvey, ML Slevin, BA Ponder, AJ Blackshaw, PF Wrigley
Journal name: 
Cancer
Citation info: 
54(6):961-964
Abstract: 
Twenty consecutive patients with a confirmed diagnosis of diffuse malignant mesothelioma of the pleura or peritoneum, previously untreated with chemotherapy, were studied in a Phase II trial of single-agent 5-fluorouracil. One partial response of 24 months was seen. Eleven patients were treated with single-agent Adriamycin (doxorubicin) after progression on 5-fluorouracil, and one partial response of 34 months was seen. It is concluded that 5-fluorouracil has only minimal activity in diffuse malignant mesothelioma. Preliminary data suggest that Adriamycin has little activity as a second-line agent.
DOI: 
http://doi.org/10.1002/1097-0142(19840915)54:6<961::aid-cncr2820540602>3.0.co;2-b
Research group: 
Ponder Group
E-pub date: 
31 Aug 1984
Users with this publication listed: 
Bruce Ponder